Journal of Experimental & Clinical Cancer Research · 2010 · 21 citations · 23 references
MedicineOncologyPharmacologyGastrointestinal OncologyMolecular OncologyNeoplasiaApoptosis In CancerApoptosis ResistanceGastrointestinal Stromal TumorsMalignant NeoplasmsOncogenic Signaling PathwaysTyrosine Kinase InhibitorsApoptosis Resistance In TumorsCancer Cell Proliferation InhibitionMetastatic Gastrointestinal Stromal TumorsTyrosine Kinase Inhibitor TherapyWestern Blot Analysis
BACKGROUND: Imatinib, a selective tyrosine kinase inhibitor, has been used as a standard first-line therapy for irresectable and metastasized gastrointestinal stromal tumor (GIST) patients. Unfortunately, most patients responding to imatinib will eventually exhibit imatinib-resistance, the cause of which is not fully understood. The serious clinical problem of imatinib-resistance demands alternative therapeutic strategy. This study was conducted to investigate the effect of all-trans retinoic acid (ATRA) on GIST cell lines. METHODS: Cell proliferation was determined by trypan blue dye exclusion test. Western blot analysis was performed to test the expression of activated KIT, its downstream proteins, and apoptosis associated proteins. The cytotoxic interactions of imatinib with ATRA were evaluated using the isobologram of Steel and Peckham. RESULTS AND CONCLUSION: In this work, for the first time we have demonstrated that ATRA affected on cell proliferation of GIST-T1 and GIST-882 cell line through inhibition of cell growth in a dose dependent manner and induced apoptosis. High dose of ATRA induced morphologic change in GIST-T1 cells, rounded-up cells, and activated the caspase-3 protein. In further examination, we found that the ATRA-induced apoptosis in GIST-T1 cells was accompanied by the down-regulated expression of survivin and up-regulated expression of Bax protein. Moreover, ATRA suppressed the activity of KIT protein in GIST-T1 cells and its downstream signal, AKT activity, but not MAPK activity. We also have demonstrated that combination of ATRA with imatinib showed additive effect by isobologram, suggesting that the combination of ATRA and imatinib may be a novel potential therapeutic option for GIST treatment. Furthermore, the scracht assay result suggested that ATRA was a potential reagent to prevent the invasion or metastasis of GIST cells.
23
Gain-of-Function Mutations of c- <i>kit</i> in Human Gastrointestinal Stromal Tumors
Seiichi Hirota, Koji Isozaki, Y Moriyama et al. · Science · 1998 · 4.5K citations
Two Hundred Gastrointestinal Stromal Tumors
Ronald P. DeMatteo, Jonathan J. Lewis, Denis H. Y. Leung et al. · Annals of Surgery · 2000 · 2.5K citations · Full text